Cardiovascular biomarkers are measurable proteins, peptides, and inflammatory markers in blood that signal myocardial injury, hemodynamic stress, or systemic inflammation — enabling clinicians and researchers to assess cardiovascular disease (CVD) risk, detect acute cardiac events, and monitor treatment response, often before a definitive clinical diagnosis is made. As CVD remains the leading cause of death worldwide, and up to 20% of coronary disease patients present without traditional risk factors, validated biomarker panels have become indispensable for both clinical risk stratification and translational research.
Established Cardiac Biomarkers
The following biomarkers have well-characterized clinical assays, defined decision thresholds, and extensive peer-reviewed validation for use in serum or plasma.
Cardiac Troponin I and T (cTnI, cTnT)
Cardiac troponins are the gold standard for detection of myocardial injury. The troponin complex regulates calcium-mediated cardiac muscle contraction; the cardiac-specific isoforms — cTnI (encoded by TNNI3) and cTnT (encoded by TNNT2) — are structurally distinct from their skeletal muscle counterparts, making them cardiac-specific markers. High-sensitivity cardiac troponin (hs-cTn) assays can detect subclinical myocardial injury at concentrations below the 99th-percentile upper reference limit, with the ability to rule in or rule out acute myocardial infarction (AMI) within 1–3 hours using the ESC 0h/1h or 0h/2h rapid-rule-out protocols. Per the Fourth Universal Definition of Myocardial Infarction (Thygesen et al., Eur Heart J 2019), a rising or falling pattern of hs-cTn with at least one value above the 99th percentile URL is required for AMI diagnosis. In population studies, chronically elevated hs-cTn — even within the "normal" range — predicts incident heart failure and cardiovascular mortality.
BNP and NT-proBNP
B-type natriuretic peptide (BNP) is secreted by ventricular cardiomyocytes in response to wall stress and volume overload. Cleavage of the proBNP prohormone yields the biologically active BNP-32 fragment and the inert N-terminal fragment NT-proBNP. NT-proBNP has a longer plasma half-life (~60–120 minutes vs. ~20 minutes for BNP) and is cleared primarily by the kidney, making NT-proBNP values sensitive to renal function — an important consideration when interpreting results in patients with chronic kidney disease. Both markers are FDA-cleared for heart failure (HF) diagnosis and prognosis: BNP >100 pg/mL and NT-proBNP >900 pg/mL (age-adjusted) are used as clinical decision thresholds for HF. In a multivariate biomarker cohort study, BNP and high-sensitivity troponin T together predicted incident heart failure with hazard ratios exceeding 2.8 in patients with chronic kidney disease (Janus et al., Eur J Heart Fail 2022).
C-Reactive Protein and High-Sensitivity CRP (hsCRP)
CRP is an acute-phase reactant produced by the liver in response to IL-6 and other inflammatory signals. Standard CRP assays detect concentrations in the range of milligrams per litre and are primarily used for infection and systemic inflammation. High-sensitivity CRP (hsCRP) assays measure lower concentrations relevant to vascular inflammation and atherosclerotic risk. Per the 2003 AHA/CDC scientific statement, hsCRP cardiovascular risk categories are: <1.0 mg/L (low), 1.0–3.0 mg/L (intermediate), and >3.0 mg/L (high cardiovascular risk). hsCRP is most useful as a supplemental risk marker in intermediate-risk individuals where it can guide statin therapy initiation decisions (JUPITER trial concept).
| Biomarker | Source tissue | Primary signal | Clinical use | FDA status |
|---|---|---|---|---|
| cTnI (TNNI3) | Cardiac myocytes | Myocardial cell injury | AMI diagnosis, ACS risk stratification | FDA-cleared (IVD) |
| cTnT (TNNT2) | Cardiac myocytes | Myocardial cell injury | AMI, HF prognosis | FDA-cleared (IVD) |
| BNP | Ventricular myocytes | Wall stress / volume overload | HF diagnosis and prognosis | FDA-cleared (IVD) |
| NT-proBNP | Ventricular myocytes | Wall stress (longer half-life) | HF diagnosis; renal clearance-sensitive | FDA-cleared (IVD) |
| CRP / hsCRP | Liver (IL-6 stimulated) | Systemic inflammation | Cardiovascular risk stratification | FDA-cleared (IVD) |
| CK-MB | Cardiac and skeletal muscle | Muscle injury (less cardiac-specific) | AMI (now largely replaced by troponin) | FDA-cleared (IVD) |
| Myoglobin | Cardiac and skeletal muscle | Rapid muscle injury marker | Early AMI detection (low specificity) | FDA-cleared (IVD) |
| D-dimer | Fibrin degradation (systemic) | Fibrinolysis / thrombosis | PE/DVT rule-out; elevated in ACS | FDA-cleared (IVD) |
Emerging and Research-Stage Cardiovascular Biomarkers
Beyond the established panel, a second tier of cardiovascular biomarkers has demonstrated predictive value in clinical cohort studies and is actively used in translational research. The following should be clearly distinguished by regulatory status:
GDF-15 (Growth Differentiation Factor 15)
GDF-15 is a divergent member of the TGF-β superfamily upregulated by oxidative stress, ischemia, and inflammatory cytokines in cardiomyocytes and macrophages. Circulating GDF-15 is a strong independent predictor of all-cause mortality and cardiovascular death in patients with established heart failure and in general populations. It is not yet a standard-of-care clinical assay and is currently used primarily in research settings. Regulatory status: not FDA-cleared as a cardiovascular IVD.
ST2 (Soluble IL1RL1)
Soluble ST2 is the soluble decoy receptor for the cytokine IL-33, produced by cardiac fibroblasts and cardiomyocytes under mechanical stretch. When IL-33 binds to soluble ST2 rather than its membrane-bound receptor, the cardioprotective IL-33/ST2 signaling axis is blocked, promoting fibrosis and adverse ventricular remodeling. High circulating ST2 concentrations correlate with worse outcomes in acute decompensated HF. Regulatory status: FDA-cleared for HF prognosis (as an aid to risk stratification).
Galectin-3
Galectin-3 is a beta-galactoside-binding lectin secreted by activated macrophages that drives cardiac fibrosis by stimulating myofibroblast proliferation and collagen deposition. Elevated plasma galectin-3 is associated with fibrotic remodeling, HF progression, and increased mortality. Regulatory status: FDA-cleared as a prognostic marker in patients with HF.
MR-proADM (Midregional Pro-Adrenomedullin)
Adrenomedullin is a vasodilatory peptide hormone. Its midregional precursor fragment (MR-proADM) is more stable in plasma and is measured as a surrogate. Elevated MR-proADM is associated with sepsis severity, acute HF, and short-term mortality. It is used clinically in Europe and increasingly in research contexts globally. Regulatory status: cleared in Europe (CE-marked); not FDA-cleared in the US as of this writing.
Circulating microRNAs (miR-1, miR-21, miR-499)
Circulating microRNAs are small non-coding RNAs released from damaged cardiomyocytes into plasma. miR-1 and miR-499 are enriched in cardiac muscle and are elevated in AMI within hours of symptom onset. miR-21 is upregulated in cardiac fibrosis and HF. Although several studies report high sensitivity for early ischemia detection, plasma miRNA measurements are highly sensitive to pre-analytical variables (hemolysis, sample handling), and no microRNA has yet reached routine clinical use. Regulatory status: research use only — no FDA-cleared miRNA cardiac assay exists as of July 2026.
Lp-PLA2 (Lipoprotein-Associated Phospholipase A2 / PLAC Test)
Lp-PLA2 is an enzyme that circulates bound to LDL particles and is expressed within atherosclerotic plaques by macrophages. It hydrolyzes oxidized phospholipids to generate pro-inflammatory lysophosphatidylcholine. Elevated Lp-PLA2 mass and activity predict coronary events independently of LDL cholesterol. The PLAC test measuring Lp-PLA2 activity is FDA-cleared as a cardiovascular risk marker in adult patients.
How Biomarker Panels Improve Cardiovascular Risk Prediction
No single cardiovascular biomarker captures the full complexity of CVD pathophysiology. Single-marker approaches are limited by the overlap between cardiac and non-cardiac conditions (troponin rises in sepsis, pulmonary embolism, and renal failure), the relatively low predictive value of any one analyte in asymptomatic populations, and the narrow dynamic range of many assays near clinical decision limits.
Multimarker strategies address these limitations by combining biomarkers that reflect distinct pathophysiological pathways. In the TIMI and GRACE risk scores for ACS, troponin is already a weighted component alongside clinical and ECG variables. The ESC 0h/1h and 0h/2h rapid-rule-out algorithms use serial hs-cTn measurements to dramatically improve diagnostic efficiency in the emergency department. The HEART score (History, ECG, Age, Risk factors, Troponin) provides a validated clinical tool for early AMI risk stratification across diverse patient populations.
At the population level, the MESA (Multi-Ethnic Study of Atherosclerosis) study demonstrated that panel approaches incorporating hsCRP, NT-proBNP, and hs-cTn reclassify a meaningful proportion of intermediate-risk individuals into high-risk or low-risk categories, improving net reclassification index (NRI) beyond traditional Framingham risk scoring. A panel of four biomarkers — BNP, high-sensitivity troponin T, FGF23, and fibrinogen — predicted incident HF in chronic kidney disease patients with NRI of 0.16 over clinical risk factors alone, confirming that even modest NRI gains translate to actionable clinical triage (Janus et al., Eur J Heart Fail 2022).
Measuring Cardiovascular Biomarkers in Research Settings
ELISA (enzyme-linked immunosorbent assay) is the primary quantification method for cardiovascular biomarkers in research laboratories. Sandwich ELISA formats are used for troponin (cTnI, cTnT), BNP, NT-proBNP, CRP, hsCRP, GDF-15, and galectin-3 measurement in serum, plasma, cell culture supernatants, and tissue homogenates.
Key performance specifications to verify when selecting a cardiovascular ELISA kit for research use:
- Sensitivity below clinical decision limits: for cardiac troponin research, assay sensitivity should ideally reach the pg/mL range (high-sensitivity format) to detect subclinical concentrations relevant to population studies. High-sensitivity ELISA kits achieve sensitivities <10 pg/mL.
- Precision (CV <10%): intra-assay and inter-assay coefficients of variation must be below 10% at concentrations near the assay's lower detection range for reliable data at clinically meaningful concentrations.
- Sample matrix validation: cardiac troponin and BNP values differ between serum and EDTA plasma due to coagulation-related proteolysis. Ensure the kit is validated in your specific matrix. Heparin plasma is generally preferred for BNP measurements; EDTA plasma is common for NT-proBNP.
- Species-specific isoform detection: cTnI and cTnT antibody epitopes are species-specific. A human cTnI assay will not reliably detect rodent cTnI in murine models — always use a species-validated kit.
BioHippo Cardiovascular Biomarker ELISA Products
BioHippo offers a validated selection of ELISA kits for cardiovascular biomarker quantification, sourced from Boster Bio, CUSABIO Technology, Bioassay Technology Laboratory, and ELK Biotechnology. Key products for cardiovascular research include:
- Human Cardiac Troponin I (cTnI) ELISA Kit — SKU CSB-E05139h, 96T. Sandwich ELISA, detection range 47–3000 pg/mL, sensitivity 11.75 pg/mL. Species: human. Validated in serum, plasma, urine. Vendor: CUSABIO.
- Human Cardiac Troponin T (cTnT) ELISA Kit — SKU CSB-E09340h, 96T. Sandwich ELISA, detection range 15.6–1000 pg/mL, sensitivity 3.9 pg/mL. Vendor: CUSABIO.
- Human High-Sensitivity Cardiac Troponin T (hs-cTnT) ELISA Kit — SKU ELK8843, detection range 15.63–1000 pg/mL, sensitivity 4.2 pg/mL. High-sensitivity format. Vendor: ELK Biotechnology.
- Human BNP ELISA Kit — SKU CSB-E07970h, 96T. Detection range 93.75–6000 pg/mL, sensitivity 23.43 pg/mL. Validated in serum, urine, tissue homogenates. Vendor: CUSABIO.
- Human hsCRP ELISA Kit — SKU CSB-E08617h, 96T. Detection range 0.625–40 ng/mL, sensitivity 0.156 ng/mL. Validated in serum, plasma, tissue homogenates. Vendor: CUSABIO.
- Human CRP ELISA Kit PicoKine® — SKU EK1316, 96T. Sandwich ELISA, sensitivity <10 pg/mL. Validated in cell culture supernatants, serum, plasma. Vendor: Boster Bio.
- Human GDF-15 ELISA Kit PicoKine® — SKU EK0767, 96T. Detection range 10–100 pg/mL range, sensitivity <10 pg/mL. Validated in serum, plasma. Vendor: Boster Bio.
- Rat BNP (NPPB) ELISA Kit — SKU E2105Ra, 96T. Detection range 5–400 ng/L, sensitivity 2.27 ng/L. Validated in serum, plasma, cell culture supernatants. Vendor: Bioassay Technology Laboratory.
Browse the full cardiovascular research catalog: ELISA kits | High-sensitivity ELISA kits.
Frequently Asked Questions
What biomarkers predict heart disease?
The best-validated biomarkers for predicting cardiovascular disease risk are cardiac troponin I (cTnI), cardiac troponin T (cTnT), B-type natriuretic peptide (BNP), NT-proBNP, and high-sensitivity C-reactive protein (hsCRP). In clinical practice, these are often used in combination with traditional risk scores (Framingham, SCORE, ASCVD). Troponin identifies myocardial injury; BNP/NT-proBNP reflects hemodynamic stress; and hsCRP captures the inflammatory component of atherosclerosis. Emerging research-stage markers including GDF-15 and ST2 provide additional prognostic depth for heart failure, while galectin-3 and Lp-PLA2 address fibrosis and plaque-based inflammation respectively.
What is troponin and why is it measured?
Cardiac troponin (cTnI and cTnT) is a structural protein complex in cardiac myofibrils that regulates actin-myosin interaction during muscle contraction. When cardiomyocytes are injured or die, troponin leaks into the bloodstream. Because the cardiac-specific isoforms (cTnI encoded by TNNI3, cTnT encoded by TNNT2) are not expressed in healthy skeletal muscle, their presence in blood is highly specific for myocardial injury. Cardiac troponin is measured to diagnose acute myocardial infarction (AMI), stratify risk in ACS patients, detect subclinical cardiac injury in chemotherapy monitoring, and evaluate heart failure severity. High-sensitivity assays (hs-cTnI, hs-cTnT) enable earlier and more sensitive detection compared to conventional troponin assays.
What does BNP measure?
BNP (B-type natriuretic peptide) measures the degree of ventricular wall stress and volume overload. It is secreted when ventricular cardiomyocytes are stretched — as occurs in heart failure, myocardial infarction, pulmonary hypertension, and volume overload states. Higher BNP concentrations indicate greater hemodynamic stress and correlate with worse HF severity (NYHA class) and prognosis. BNP and its N-terminal cleavage product NT-proBNP are both used clinically; NT-proBNP has a longer half-life (~60–120 min vs. ~20 min for BNP) and is renally cleared, so renal function must be considered when interpreting NT-proBNP results. Normal BNP is typically <100 pg/mL; HF is unlikely when BNP is <35 pg/mL (age- and context-specific thresholds apply).
What is the difference between hsCRP and CRP?
CRP and hsCRP measure the same protein — C-reactive protein — but at different concentration ranges. Standard CRP assays are calibrated for elevated inflammatory states (above ~8 mg/L) such as bacterial infection. High-sensitivity CRP (hsCRP) assays are calibrated to detect the lower concentrations (0.5–10 mg/L) relevant to chronic vascular inflammation and atherosclerotic risk assessment. For cardiovascular risk stratification, only hsCRP is appropriate: <1.0 mg/L indicates low risk, 1.0–3.0 mg/L intermediate risk, and >3.0 mg/L high cardiovascular risk, per the 2003 AHA/CDC guidelines. Using standard CRP values for cardiovascular risk prediction is not appropriate because many at-risk patients have concentrations below the standard assay's detection limit.
How accurate are cardiovascular biomarkers at predicting heart disease risk?
Individual cardiovascular biomarkers have moderate predictive accuracy (AUC 0.60–0.75 for single markers) when used in isolation. Their value is greatest when combined with clinical risk scores. hsCRP adds incremental predictive value beyond Framingham risk score, particularly in the intermediate-risk stratum. High-sensitivity troponin T detects subclinical myocardial injury years before clinical heart failure and independently predicts cardiovascular mortality in population studies. BNP improves discrimination for heart failure risk. Multimarker panels — particularly combining hs-cTn, BNP/NT-proBNP, and hsCRP — improve net reclassification and reduce the proportion of patients incorrectly classified as intermediate risk. No biomarker panel is sufficient alone; clinical context, imaging, and patient history are always required for complete cardiovascular risk assessment.
Can ELISA kits measure cardiac biomarkers in research?
Yes — ELISA is the standard quantification method for cardiac biomarkers in research applications including translational studies, animal model experiments, drug efficacy studies, and biobank analysis. Research-grade ELISA kits for cTnI, cTnT, BNP, NT-proBNP, hsCRP, and GDF-15 are available for human samples as well as preclinical species (mouse, rat, rabbit, canine). Key considerations: (1) use cardiac-specific antibodies validated against the cardiac isoforms, not cross-reactive skeletal muscle assays; (2) verify sample matrix compatibility (serum vs. EDTA plasma vs. heparin plasma); (3) for sub-clinical concentration ranges, select high-sensitivity formats with sensitivity below 10 pg/mL; (4) confirm assay CV <10% at the concentration of interest. BioHippo stocks validated kits from Boster Bio, CUSABIO, Bioassay Technology Laboratory, and ELK Biotechnology for all major cardiac biomarkers.
References
1. Thygesen K, et al. Fourth Universal Definition of Myocardial Infarction (2018). Eur Heart J. 2019;40(3):226. doi:10.1093/eurheartj/ehy856
2. Janus SE, et al. Multi-variable biomarker approach in identifying incident heart failure in chronic kidney disease. Eur J Heart Fail. 2022;24(6):988–995. doi:10.1002/ejhf.2543
3. Wang TJ, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med. 2006;355(25):2631–2639.
4. Blankenberg S, et al. Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts. Circulation. 2010;121(22):2388–2397.
5. AHA/CDC Scientific Statement on hsCRP in cardiovascular risk assessment. Circulation. 2003;107(3):499–511.